ESMO Congress 2026

The treatment landscape of ovarian cancer is increasingly reshaped by molecularly guided targeted therapy. A treatment-algorithm review notes that most patients are diagnosed only at advanced stages, when survival outcomes are worse and therapeutic decisions more challenging; standard treatment comprises debulking surgery whenever possible and systemic therapy (chemotherapy, targeted and antiangiogenic agents), while early genetic testing of germline and somatic mutations involved in DNA repair and the clinical development of targeted agents have become core components of patient-tailored strategies ^[2]. Meanwhile, epithelial ovarian cancer remains the deadliest gynecologic malignancy, reliable predictive biomarkers are insufficient, and liquid-biopsy-accessible sB7-H4 and circulating tumor cells have been shown to be independent prognostic factors for overall survival ^[3]; the curatedOvarianData transcriptome database, covering 2970 patients from 23 studies, enables molecularly defined patient-subgroup stratification and immediate meta-analysis, through which CXCL12 was confirmed to be associated with survival ^[1]. Together, these data show that treatment options and predictive tools for advanced and recurrent ovarian cancer remain clearly insufficient, providing direct clinical context for developing new targeted agents in platinum-resistant, heavily pretreated populations.

At #ESMO26 in Madrid, Zymeworks shared new Phase 1 data on its investigational FRα-targeting antibody-drug conjugate (ADC) in heavily pretreated patients with platinum-resistant ovarian cancer, stating that the results reinforce its confidence in the potential of this approach to help expand treatment options for patients. Notably, the live post itself contains no specific figures — response rates, enrolled patient numbers, dose levels and safety details are all undisclosed, with full key data to be found in the company press release and specific values pending confirmation.

The conference feed also included a Medscape post announcing a satellite symposium featuring Prof. Susana Banerjee on novel targeted agents in platinum-resistant ovarian cancer (booth #8072); this is an educational satellite activity, not a primary trial readout. As for the step forward, the algorithm summarized in ^[2] has established the pathway of deploying targeted agents in primary and recurrent disease according to tumor molecular features, and this Phase 1 dataset adds new clinical evidence advancing the FRα-targeting ADC route in platinum-resistant, heavily pretreated patients; against the gap in prognostic and response-prediction tools noted in ^[3], the benefit of such target selection currently still has to be supported by clinical readouts themselves.

The limitations are equally clear: this is an early Phase 1 readout, the live post discloses no specific efficacy or safety numbers, and sample size and follow-up details are pending confirmation; the background literature contains no pivotal trials of same-class ADCs for direct comparison, so no judgment can currently be made on the relative merits of this readout or its subsequent development path.